NASDAQ$SMTI

Sanara MedTech Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Announced third quarter 2021 results, demonstrating revenue growth despite challenges from the COVID-19 Delta variant surge.

Sanara MedTech reported a 35% increase in revenue compared to the same quarter last year, despite the impact of the COVID-19 Delta variant on elective procedures. The company experienced a higher net loss due to increased SG&A expenses related to sales force expansion and the addition of Rochal Industries, LLC.

  • Revenues increased by 35% compared to the third quarter of 2020, reaching $5,823,942.
  • The company's sales were impacted by the COVID-19 Delta variant surge in key markets.
  • Net loss increased due to higher SG&A expenses, primarily driven by sales force expansion and increased selling costs.
  • The company continued to execute its wound and skin care strategy by gaining new hospital approvals and expanding into new facilities.

Headline financials

Total Revenue

$5.82M

Previous: $4.31M+35.2%
EPS (adj)

-$0.27

Previous: -$0.18-50.0%
Capital Expenditures

-$30.2K

Previous: -$57.5K+47.5%
Free Cash Flow

-$2.08M

Previous: -$1.2M-72.5%
Net Income

-$2.05M

Previous: -$1.15M-78.5%
Operating Income

-$1.85M

Previous: -$1.31M-41.9%
Gross Profit

$5.31M

Previous: $3.86M+37.5%
Cash & Equivalents

$22.4M

Previous: $2.12M+955.1%
Total Assets

$37.9M

Previous: $9.65M+293.0%
Stock-Based Comp

$229K

Previous: $382K-40.0%

Revenue & EPS history

Sanara MedTech · Revenue · Quarterly

$5.82M

Q3 2021+35.2%vs Q3 2020
Beat estimate in 3 of 5 quarters(60%)
ActualEstimate

Revenue by segment

Sanara MedTech · $31.6M total across 2 segments · Q2 2023

  • Soft tissue repair
    $15.8M
  • Bone fusion products
    $15.8M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+0.2%

Avg return

Earnings day

-2.3%

Avg return

5 days after

+1.0%

Avg return

30 days after

34%

22 / 64 earnings

Positive

+28.6%

Q4 2014

Best reaction

-25.0%

Q3 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+13.0%+17.3%
Q4 2025-0.3%-7.5%+4.3%
Q3 2025-23.4%-24.9%-7.6%
Q1 2025-9.0%-11.2%-17.9%
Q4 2024-12.6%-15.4%-10.4%
Q3 2024+6.3%-1.0%+2.5%
Q2 2024+14.9%+16.3%+20.2%
Q1 2024-5.0%-2.9%-0.5%
Q4 2023-1.8%-1.1%-13.1%
Q3 2023+18.8%+15.3%+37.5%
Q2 2023-12.5%-13.6%-22.6%
Q1 2023-5.0%-9.2%-5.9%
Q4 2022-0.1%-4.1%+17.9%
Q3 2022+4.1%+7.2%+3.2%
Q2 2022+1.2%-1.7%+13.4%
Q1 2022+5.0%+2.3%-12.2%
Q4 2021+2.5%+10.7%-10.9%
Q3 2021-1.6%-2.2%-15.8%
Q2 2021-8.3%-12.4%-14.5%
Q1 2021+5.2%+14.9%+28.7%
Q4 2020+14.5%+6.8%-4.5%
Q3 2020-4.5%-4.3%+15.7%
Q2 2020+9.8%+13.7%+37.2%
Q1 2020-20.7%-18.2%+28.8%
Q4 2019-4.3%+7.3%+30.9%
Q3 2019-3.9%-5.7%+5.1%
Q2 2019-11.5%-20.1%-17.2%
Q1 2019+0.0%-16.7%-16.7%
Q4 2018+0.0%-16.7%-16.7%
Q3 2018+0.0%+0.0%+0.0%
Q2 2018-10.0%-10.0%-30.0%
Q1 2018+20.0%+0.0%+20.0%
Q4 2017+20.0%+0.0%+20.0%
Q3 2017+0.0%+0.0%-14.3%
Q2 2017+0.0%+16.7%+16.7%
Q1 2017+0.0%+0.0%-22.2%
Q4 2016+0.0%+0.0%-10.0%
Q3 2016-20.0%-20.0%+0.0%
Q2 2016+20.0%+0.0%+0.0%
Q1 2016+0.0%
Q4 2015+0.0%
Q3 2015+0.0%
Q2 2015+0.0%
Q1 2015+11.1%
Q4 2014+28.6%
Q3 2014+0.0%
Q2 2014+0.0%
Q1 2014+0.0%
Q4 2013+0.0%
Q3 2013+14.3%
Q2 2013+0.0%
Q1 2013+16.7%
Q4 2012-12.5%
Q3 2012-16.7%
Q2 2012+6.7%
Q1 2012+0.0%
Q4 2011-4.3%
Q3 2011+0.0%
Q2 2011-10.3%
Q1 2011-11.1%
Q4 2010+3.1%
Q3 2010-25.0%
Q2 2010+2.9%
Q1 2010+5.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro